Optimi Health to Launch Phase 3 MDMA Trial for PTSD in 2027
OPTH sits 54% above its 52-week low of $3.485.
Summary
Optimi Health announced a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD, enrolling up to 100 veterans and frontline workers across multiple Canadian sites, with initiation expected in 2027. This follows the company's Phase 2 psilocybin trial for major depressive disorder announced on September 10, marking a significant expansion of its clinical pipeline into late-stage development. The trial will use Optimi's synthetic MDMA HCl in two supervised sessions, with the primary endpoint being change in CAPS-5 scores. While no market authorization exists yet, the company already supplies MDMA to Australian clinics under the Authorized Prescriber Scheme, providing commercial validation. The announcement strengthens Optimi's position in the psychedelic therapeutics space, though the 2027 start date tempers near-term impact.
At the time of this announcement, OPTH was trading at $5.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29M. The 52-week trading range was $3.49 to $8.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.